Treatment of Classical Hodgkin Lymphoma in Children and Adolescents (Age 18 or Younger) — Intermediate Risk

Clinical Scenario

This protocol addresses classical Hodgkin lymphoma in children and adolescents aged 18 years or younger who fall into the intermediate-risk category. Management in this age group follows a dedicated pediatric framework with specific staging thresholds and response-adapted goals.

Intermediate-Risk Staging — Qualifying Presentations

Age ≤18 years

The intermediate-risk group encompasses the following disease stages:

Non-bulky stage IB
Non-bulky stage IIB
Bulky stage IA
Bulky stage IIA
Stage IIA_E
Stage IIIA

Primary Clinical Goal

A central measure of treatment success is achieving a rapid early response to initial therapy. Monitoring of early-treatment response guides further management decisions in this population.

Treatment Approach — Partial Overview

+ more

First-line treatment is built around a pediatric chemotherapy regimen; select protocols additionally incorporate radiation therapy. Several regimen options are available for intermediate-risk disease — the complete evidence-based algorithm, including all options and their sequencing, is contained in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Intermediate-Risk Disease (non-bulky stage IB or IIB, bulky stage IA or IIA, stage IIA_E, stage IIIA)

Intermediate-Risk Disease: COPP/ABV, ABVE-PC, OEPA or OPPA plus COPP or COPDAC

A patient who responds quickly to initial treatment is considered a rapid early responder (RER).

View source ↗